Back to Search
Start Over
Bausch Faces $3 Billion in Claims Left From Valeant Stock Suit.
- Source :
- Bloomberg.com; 7/30/2021, p1-2, 2p
- Publication Year :
- 2021
-
Abstract
- Keywords: 0947744D; 1070L; BHC@CN; ALLTOP; BUSINESS; CANADA; CONS; CONSS; COS; DRG; HEA; INDUSTRIES; LAW; NORTHAM; TOP; US; WORLD; WWTOP; WWTOPAM EN 0947744D 1070L BHC@CN ALLTOP BUSINESS CANADA CONS CONSS COS DRG HEA INDUSTRIES LAW NORTHAM TOP US WORLD WWTOP WWTOPAM Bausch Health Cos. owes a group of investment funds more than $3 billion for stock losses caused by spurious accounting at its predecessor, Valeant Pharmaceuticals, investors suing the company alleged this week. QX27SYT0G1KW (Bloomberg)--Bausch Health Cos. owes a group of investment funds more than $3 billion for stock losses caused by spurious accounting at its predecessor, Valeant Pharmaceuticals, investors suing the company alleged this week. [Extracted from the article]
- Subjects :
- STOCKS (Finance)
CHIEF financial officers
ACTIONS & defenses (Law)
Subjects
Details
- Language :
- English
- Database :
- Complementary Index
- Journal :
- Bloomberg.com
- Publication Type :
- Periodical
- Accession number :
- 151746968